The Food and Drug Administration this week cleared a second species of cadaver-eating fly to be used in the treatment of canker sores. An announcement from Cuprina Holdingsa Singapore-based company that has named its new therapeutic maggots MediFly Maggots.
With the clearance, Cuprina appears to be the only company with FDA approval to sell two types of fly larvae, which has the potential to dominate the global worm market.
It is a new type Lucilia is coveredor the Australian sheep fly. He is a close relative Lucilia sericataor the common green bottle fly, is the most common type of fly used for wound healing, usually in biosurgery or debridement treatment of worms (MDT). L. sericata It is the only other fly that the agency first granted FDA approval to Ronald Sherman in 2004. is now the Medical and Scientific Director of Cuprina.
“We now have FDA clearance for both types used in MDT, a position no other company has,” Cuprina CEO David Quek said in a statement. “This solidifies our wound care platform in one of the world’s most demanding regulatory markets and gives us a defensible advantage as we continue to build our portfolio.”
The company makes no claims of any significant therapeutic difference between the two worm treatments. Rather, they seem to suit different markets. L. sericata Cuprina says the West is more familiar with wound care L. cuprina It is better known in Australia, Africa, Asia and part of the Americas.
For his part, Sherman, a longtime champion of the remedies, hailed the formalization as a step forward for MDT in general. “Maggot debridement therapy has earned its place in modern wound care, and adding a second FDA-cleared variant strengthens the entire field,” Sherman said. “Lucilia was covered has meaningful international experience, and bringing it under US FDA approval (ing) gives clinicians and their patients more flexibility in how this therapy is administered.
